Aiyibotong, which has installed CDSS in over 200 healthcare institutions in China, is expanding its product portfolio to include broader clinical quality assurance systems. The collaboration will also involve developing an AI voice agent to assist marginalized communities. The partnership is set against the backdrop of a growing digital health market in China, projected to reach US$45 billion by 2025, with the CDSS market expected to double by 2030. Both companies aim to create a hybrid model-driven CDSS that combines Aiyibotong's experience and data with Treatment's technology to enhance their global product offerings.
Key takeaways:
- Treatment.com AI and Aiyibotong have signed a Collaborative Agreement to enhance clinical decision support in China and the Far East using AI and machine learning technologies.
- The market for Clinical Decision Support Systems (CDSS) in China is expected to reach approximately US$600 million by 2030.
- Aiyibotong has installed its CDSS systems in over 200 healthcare institutions in China and is expanding its product portfolio to include broader clinical quality assurance systems.
- The collaboration aims to localize Treatment's Global Library of Medicine content for the Chinese market and explore co-marketing opportunities targeting healthcare institutions and universities.